Lifecore Biomedical Q1 Preview: $25.96M Revenue, 17.2% Upside
LFCR•Lifecore Biomedical plans to report Q1 results on May 6, 2026 with projected revenue of $25.96 million and an EPS loss of $0.27. Barrington raised its price target to $6.00 from $5.50, implying a 17.19% upside while highlighting a current ratio of 3.49 and debt-to-equity of 4.23.
1. Q1 Earnings Expectations
Lifecore Biomedical will report first-quarter results on May 6, 2026, with analysts projecting revenue of $25.96 million and an EPS loss of $0.27, reflecting ongoing investment in its CDMO operations.
2. Analyst Price Target Increase
Barrington raised its price target to $6.00 from $5.50, implying a 17.19% upside based on the current share price and signaling confidence in upcoming contract manufacturing growth.
3. Key Financial Ratios
The company trades at a negative P/E of -5.69, holds a robust current ratio of 3.49 and relies on debt-to-equity of 4.23, while its price-to-sales and enterprise value-to-sales ratios stand at 1.31 and 2.17 respectively.
